This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Multivitamins parenteral


Powder for solution for injection or infusion containing multivitamins

Drugs List

  • CERNEVIT powder for solution for injection
  • multivitamins powder for solution for injection
  • Therapeutic Indications


    Parenteral nutritional support
    Supplement in malabsorption syndromes



    One vial per day.


    One vial per day.


    Children over 11 years
    One vial per day.


    By slow intravenous injection over at least 10 minutes or by intravenous infusion in a solution of 5% glucose or 0.9% sodium chloride solution for infusion.


    Children under 11 years
    Hypervitaminosis A
    Hypervitaminosis D
    Restricted sodium intake
    Hypersensitivity to arachis oil (peanuts)

    Precautions and Warnings

    Hepatic impairment
    Renal impairment

    Contains more than 1 mmol (23 mg) sodium per dose
    Contains soya or soya derivative
    This preparation does not contain vitamin K
    Do not mix with other drugs/substances unless compatibility known
    Injection should be given by slow injection over not less than 10 minutes
    Resuscitation facilities must be immediately available
    Assess vitamin B12 status prior to administration
    Monitor fat soluble vitamins during long term therapy
    Monitor hepatic function
    May cause anaphylactic / anaphylactoid reactions
    May affect results of some laboratory tests
    Discontinue if severe hypersensitivity reactions occur

    Refeeding syndrome may result in severely undernourished patients. Careful monitoring and slowly increasing nutrient intakes while avoiding overfeeding can prevent it. Should nutrient deficiencies occur, appropriate supplementation may be necessary.

    Monitoring of hepatic function is recommended and closely in patients with hepatic jaundice or other evidence of cholestasis.

    Hepatobiliary disorders including cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure, as well as cholecystitis and cholelithiasis are known to develop in some patients on parenteral nutrition. Patients developing abnormal laboratory parameters or other signs of hepatobiliary disorders should be assessed early in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

    Patients with hepatic impairment may need individualised vitamin supplementation because the presence of liver disease is associated with increased susceptibility to vitamin A toxicity.

    Patients with renal impairment may need individualised vitamin supplementation, depending on the degree of impairment and the presence of concomitant medical conditions.

    In severe renal impairment ensure adequate vitamin D status is maintained and vitamin A toxicity prevented, which may develop in such patients with low-dose vitamin A supplementation or even without supplementation.

    Cross-allergic reactions between soybean and peanut proteins have been observed.

    Allow for vitamins from other sources.

    Monitor blood vitamin concentrations in long term use to ensure maintenance of adequate levels and to avoid overdose and toxic effects.

    The solution, infusion set and catheter should be periodically checked for precipitates.

    Pregnancy and Lactation


    The preparation should be used with caution during pregnancy.

    The vitamin requirements for pregnant women may exceed those of non-pregnant women. The manufacturer advises that pregnant women should follow recommended daily allowances for their condition. Careful consideration should be given to the potential risks and benefits for each specific patient before administering the preparation.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    The preparation is contraindicated during breastfeeding.

    The manufacturer advises that breastfeeding is not recommended because of the risk of vitamin A overdose in the neonate.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Alanine aminotransferase increased
    Bile acids increased
    Cardiac arrest
    Chest discomfort
    Epigastric discomfort
    Gamma glutamyl transferase (GGT) increased
    General aches
    Glutamate dehydrogenase increased
    Hypersensitivity reactions
    Increase in alkaline phosphatase
    Increase in serum transaminases
    Infusion related reaction
    Local pain (injection site)
    Respiratory distress
    Retinol binding protein increased
    Throat tightness
    Vitamin A increased


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: May 2016

    Reference Sources

    Joint Formulary Committee. British National Formulary. 71st ed. London: BMJ Group and Pharmaceutical Press; 2016.

    Summary of Product Characteristics: Cernevit. Baxter Healthcare Ltd. Revised March 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.